Dexmedetomidine as a Sedative in the Awake Implantation of a Neuromodulative System

Bruggen, Feline F J A Ter; Eralp, Ismail; Leliveld, Leo; Jansen, Chris; Stronks, Dirk L.; Huygen, Frank

doi:10.1111/papr.12425

Cited by 8 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This report seems to be in contradiction with our own proof‐of‐concept study in which we describe the successful application of dexmedetomidine in the awake implantation of a neuromodulative system …”

Section: In Responsecontrasting

confidence: 97%

Dexmedetomidine Infusion may Cause Agitation During Procedural Sedation

Banik

Huygen³

2016

Pain Practice

View full text Add to dashboard Cite

Section: In Responsecontrasting

confidence: 97%

Dexmedetomidine Infusion may Cause Agitation During Procedural Sedation

Banik

Huygen³

2016

Pain Practice

View full text Add to dashboard Cite

“…On the other hand, respiratory depression is an important side effect of other sedatives such as propofol, benzodiazepines, and opioids. The main side effects of dexmedetomidine are hypotension and both effects disappear quickly after stopping the infusion (1,(8)(9)(10).…”

Section: Discussionmentioning

confidence: 99%

“…Regarding the need for perioperative evaluation of the stimulation pattern, we investigated the efficacy of dexmedetomidine as sedative. It has been shown by ter Bruggen et al that percutaneous lead placement with dexmedetomidine as a sedative is safe and comfortable for patient and surgeon (1). There is also a case report by Harned et al where dexmedetomindine was used for surgical lead placement via laminectomy (2).…”

Section: Introductionmentioning

confidence: 99%

Conscious Sedation Using Dexmedetomidine During Surgical Paddle Lead Placement Improves Outcome in Spinal Cord Stimulation: A Case Series of 25 Consecutive Patients

Vanhauwaert

Couvreur

Vandebroek

et al. 2021

Neuromodulation: Technology at the Neural Interface

View full text Add to dashboard Cite

“…Dexmedetomidine is an alpha-2 agonist with sedative, analgesic, and anxiolytic properties, known for its ability to produce arousable sedation in a moderately sedated patient, with spontaneous ventilation. 8 Previous studies have reported promising results regarding the use of dexmedetomidine in awake procedures, such as during an awake craniotomy and during the surgical implantation of paddle lead electrodes for neurostimulation through alaminectomy. 9,10 In the DexMedPro trial, we compared dexmedetomidine with propofol during the implantation of a neurostimulator -as a sedative agent -in terms of patient satisfaction and safety.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Effects of Dexmedetomidine versus Propofol During the Implantation of a Neurostimulator—A Post-Trial Follow-Up Analysis

Bruggen

Redekop

Stronks

et al. 2021

JPR

View full text Add to dashboard Cite

Objective: The success of neurostimulation depends partly on the amount of coverage of the neurostimulation-induced paresthesia of the painful area. This is often achieved by asking feedback from patients intraoperatively. If sedation analgesia is used, it is important that the patient is comfortable during sedation and easily arousable. If the patient is not well sedated or experiences residual effects of the sedation during testing, this can directly influence the ideal placement of the leads and indirectly the long-term effect of the treatment. It is our hypothesis that the quality of the sedation is directly coupled to the adequacy of lead placement and in this way in the result of the treatment. Dexmedetomidine is known for its easy production of arousable sedation. The aim of the present study was to compare the long-term effect of using dexmedetomidine versus propofol during the implantation of a neurostimulator. Materials and Methods: This is a post-trial follow-up analysis of the DexMedPro cohort. The primary outcome was global perceived effect (GPE). The secondary outcomes were the course of pain intensity, the emotional and physical functioning at the time of follow-up, and the course of neurostimulation treatment. In this study, we used the patient satisfaction with sedation as a measure for sedation quality. Results: Regarding the GPE, no statistically significant differences were found between the experimental groups in either subscale (ie, recovery (p=0.82) and satisfaction with the neurostimulation treatment at follow-up (p=0.06)). The same was found regarding the secondary parameters. A correlation was found between patient satisfaction with sedation during the lead implantation (side effects and procedural recall) and satisfaction at follow-up. Conclusion: Regarding the long-term efficacy of neurostimulation treatment, no statistically significant differences were found between the dexmedetomidine and the propofol group. We observed a trend towards greater satisfaction with the neurostimulation treatment at followup in the dexmedetomidine group, compared to the propofol group.

show abstract

Dexmedetomidine as a Sedative in the Awake Implantation of a Neuromodulative System

Cited by 8 publications

References 12 publications

Dexmedetomidine Infusion may Cause Agitation During Procedural Sedation

Dexmedetomidine Infusion may Cause Agitation During Procedural Sedation

Conscious Sedation Using Dexmedetomidine During Surgical Paddle Lead Placement Improves Outcome in Spinal Cord Stimulation: A Case Series of 25 Consecutive Patients

Long-Term Effects of Dexmedetomidine versus Propofol During the Implantation of a Neurostimulator—A Post-Trial Follow-Up Analysis

Contact Info

Product

Resources

About